With Democrats gaining a majority in the US House of Representatives following the 2018 midterm elections, drug pricing hearings became an inevitability.
For now, it seems the focus of legislators is zeroed in on the individual, rather than the entity, as Trump’s FDA Commissioner Scott Gottleib seems a more likely target for a subpoena than any other FDA group or individual.
Get the experts’ take on what may come next in the legislation of drug pricing in this informative Pink Sheet article.
For now, it seems the focus of legislators is zeroed in on the individual, rather than the entity, as Trump’s FDA Commissioner Scott Gottleib seems a more likely target for a subpoena than any other FDA group or individual.
Get the experts’ take on what may come next in the legislation of drug pricing in this informative Pink Sheet article.
